Penfluridol induced extrapyramidal symptoms (eps): A case report

Sereen Rose Thomson, Balaji Ommurugan, Shalini Adiga, Navin Patil, Reddy Saurish Reddy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Penfluridol is a long acting oral antipsychotic agent taken once a week for the treatment of schizophrenia and other psychotic disorders. The weekly dosage regimen of the drug makes it an ideal drug in non-compliant patients, which is commonly seen in 50-75% of psychotic disorder patients. Better compliance may be associated with fewer relapses, better quality of life, fewer crises and less or shorter hospitalizations, leading to lower costs. As a part of pharmacovigilance program of India, we hereby report a case of Penfluridol induced extrapyramidal symptoms in a patient with refractory schizophrenia who developed EPS even at the least possible dose of the drug. Relevant data was collected from case record as per Central Drug Standard Control Organisation form and causality, severity and preventability assessment was done as per Naranjo's, Hartwigs and Schumock and Thornton scales respectively.

Original languageEnglish
Pages (from-to)214-216
Number of pages3
JournalJournal of Applied Pharmaceutical Science
Volume7
Issue number1
DOIs
Publication statusPublished - 01-01-2017

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Penfluridol induced extrapyramidal symptoms (eps): A case report'. Together they form a unique fingerprint.

  • Cite this